Accessibility Menu
ValiRx Plc logo

ValiRx Plc(LSE) VAL

Current Price£0.00
Market Cap£2.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-100%
5 Year-99%
1 Year-73%
1 Month-9%
ValiRx Plc last closing stock price
MetricPriceDate
Last closeGBX 0.162026-07-24
ValiRx Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%GBX 0.162026-07-17
1 month-8.57%GBX 0.182026-06-24
3 month-42.86%GBX 0.282026-04-24
Year to date-52.24%GBX 0.342025-12-31
1 year-73.33%GBX 0.602025-07-24
3 year-97.63%GBX 6.752023-07-25
5 year-99.12%GBX 18.252021-07-23
Since inception-100%GBX 6,797.622006-10-03

ValiRx Plc Financials at a Glance

Market Cap

£2.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£81.15K

Net Income (TTM)

-£4.15M

EPS (TTM)

-£0.01

P/E Ratio

-0.30

Dividend

£0.00

Beta (Volatility)

-0.05 (Low)

Price

£0.00

Volume

700,567

Open

£0.00

Previous Close

£0.00

Daily Range

£0.00 - £0.00

52-Week Range

£0.00 - £0.01

Estimated Earnings Date

Jun 10, 2026

VAL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ValiRx Plc

ValiRx plc is a UK-based biopharmaceutical company focused on developing innovative oncology therapeutics and companion diagnostics. The company is advancing several drug candidates aimed at treating various cancers and other serious health conditions.

Products and Services
  • VAL201: A small molecule targeting prostate and hormone-dependent cancers
  • VAL401: A reimagined antipsychotic for non-small cell lung cancer
  • VAL301: A peptide in pre-clinical development for endometriosis
Growth Outlook
  • Pipeline includes multiple candidates in various stages of clinical trials
  • Recent advancements in VAL401 show promise for lung cancer treatment
  • Focus on expanding therapeutic applications may enhance market reach
Financial Highlights
  • Recent quarterly revenue of £31,371, reflecting ongoing development costs
  • Cash and cash equivalents increased to £791,612 in Q4 2025
  • Current ratio of 4.62 indicates strong liquidity position
AI Generated • Jul 17, 2026

Industry

Biotechnology

CEO

Mark Edward Eccleston, PhD, MBA

Headquarters

London, GL CM22 7BD, GB

VAL Financials

Key Financial Metrics (TTM)

Gross Margin

-407.60%

Operating Margin

-5809.39%

Net Income Margin

-7115.36%

Return on Equity

-70.79%

Return on Capital

-63.80%

Return on Assets

-84.82%

Earnings Yield

-3.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£2.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.32B

Volume

700.57K

Avg. Volume

13.47M

Financials (TTM)

Gross Profit

-£345.09K

Operating Income

-£3.99M

EBITDA

-£3.53M

Operating Cash Flow

-£3.09M

Capital Expenditure

-£51.74K

Free Cash Flow

-£3.15M

Cash & ST Invst.

£791.61K

Total Debt

£1.40K

ValiRx Plc Performance Analysis

ValiRx Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 0N/A
20232023-12-31GBP 9,600N/A
20242024-12-31GBP 49,775418.5%
20252025-12-31GBP 31,372-37.0%
ValiRx Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-100.0%
Q42024-12-31N/A
Q22025-06-30-100.0%
Q42025-12-31N/A
ValiRx Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.0330.8%
20232023-12-31GBP -0.02-34.3%
20242024-12-31GBP -0.01-27.9%
20252025-12-31GBP -0.01-62.8%
ValiRx Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3024.5%
Q42024-12-314.1%
Q22025-06-3069.0%
Q42025-12-3113.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£31.37K

+226.8%

Gross Profit

-£6.25K

+95.1%

Gross Margin

-19.92%

N/A

Market Cap

£2.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£132.03K

N/A

Employees

16

N/A

Net Income

-£1.39M

-39.1%

EBITDA

-£888.53K

+12.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£791.61K

+353.2%

Total Debt

£1.40K

-93.7%

Accounts Receivable

£225.35K

N/A

Inventory

£69.00K

N/A

Long Term Debt

£0.00

-100.0%

Short Term Debt

£1.40K

-86.3%

Return on Assets

-84.82%

N/A

Return on Invested Capital

-76.05%

N/A

Free Cash Flow

-£519.16K

+22.6%

Operating Cash Flow

-£516.57K

+22.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PYC.LPhysiomics Plc
£0.00-5.00%
FDBK.LFeedback plc
£0.06+0.00%
FUM.LFutura Medical plc
£0.00+0.00%
NFX.LNuformix plc
£0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
SOFISoFi Technologies
$16.46-0.01%
FFord Motor Company
$14.37+0.02%

Questions About VAL

What is the current price of ValiRx Plc?

ValiRx Plc is trading at £0.00 per share.

What is the 52-week range for ValiRx Plc?

Over the past 52 weeks, ValiRx Plc has traded between £0.00 and £0.01.

How much debt does ValiRx Plc have?

As of the most recent reporting period, ValiRx Plc reported total debt of £1.40K.

How much cash does ValiRx Plc have on hand?

ValiRx Plc reported £791.61K in cash and cash equivalents in its most recent financial results.

What is ValiRx Plc’s dividend yield?

ValiRx Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.